August 5, 2026 — Leads & Copy — Glucotrack, Inc. has secured approximately $5.5 million in financing from institutional investors through a combination of equity and convertible debt. The financing includes a $2.0 million equity offering and a $3.5 million follow-on investment in convertible debt.
The equity financing features units priced at $0.75 each. Every unit consists of one share of common stock, or an equivalent security, and a five-year warrant exercisable at $1.50 per share.
“We believe one of the strongest signals investors can send is choosing to increase their alignment with common shareholders,” said Erik Emerson, Chief Executive Officer of Glucotrack. “This financing strengthens our balance sheet, provides additional growth capital, and reflects confidence in our long-term strategy. We believe it positions us well as we continue executing across our portfolio of opportunities.”
E.F. Hutton & Co. acted as the exclusive advisor to Lōkahi Therapeutics™, a subsidiary of Glucotrack, in connection with this transaction.
Glucotrack, Inc. operates Lōkahi and, through its subsidiary Glucotrack Technologies, Inc., is focused on developing novel technologies for individuals with diabetes. This includes work on a long-term implantable continuous blood glucose monitoring system, the Glucotrack CBGM, which is currently an Investigational Device limited to investigational use by federal law in the United States.
Lōkahi Therapeutics is a biopharmaceutical platform company concentrating on identifying, evaluating, acquiring, and advancing therapeutic assets. It utilizes its ai² platform and ai² Futures Lab execution model, integrating expertise and decision-making to foster strategic development and value creation.
E.F. Hutton & Co. is a full-service investment bank and broker-dealer based in New York City, providing investment banking and capital markets services to corporations, financial sponsors, and institutional investors globally.
Source: Glucotrack, Inc.
